Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft

Purpose Sabarubicin (MEN 10755), a new disaccaride anthracycline, has shown greater efficacy than Doxorubicin in a large panel of preclinical models and now it is in phase II clinical trials. Its promising antitumour activity promoted considerable interest to combine Sabarubicin with other antitumou...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2008-09, Vol.62 (4), p.621-629
Hauptverfasser:	Bigioni, M., Benzo, A., Irrissuto, C., Lopez, G., Curatella, B., Maggi, C. A., Manzini, S., Crea, A., Caroli, S., Cubadda, F., Binaschi, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Cell Survival - drug effects Cisplatin - administration & dosage Disaccharides - administration & dosage Dose-Response Relationship, Drug Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Drug Administration Schedule Drug Combinations Drug Synergism Female Humans Injections, Intravenous Lung Neoplasms - drug therapy Lung Neoplasms - pathology Medical sciences Medicine Medicine & Public Health Mice Mice, Nude Neoplasm Transplantation Oncology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Pneumology Transplantation, Heterologous Tumors of the respiratory system and mediastinum Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!